# **Human IGFBP7 Knockdown Cell Line (WB-Validated)**



**Catalog #: C63291** 

#### **Aliases**

IGFBP7; Insulin Like Growth Factor Binding Protein 7; IGFBP-7; MAC25; PSF; FSTL2; Insulin-Like Growth Factor-Binding Protein 7; Prostacyclin-Stimulating Factor; Tumor-Derived Adhesion Factor; PGI2-Stimulating Factor; IGF-Binding Protein 7; IGFBP-RP1; IBP-7; TAF; Insulin-Like Growth Factor Binding Protein 7; MAC25 Protein; Angiomodulin; IGFBP-7v; IGFBPRP1; RAMSVPS; AGM

# **Background**

Gene Name: IGFBP7 NCBI Gene Entry: 3490

# **Storage**

Store at liquid nitrogen for 1 year.

# **Kit Components**

- 1. Human IGFBP7 Knockdown Cell Line (Wb-Validated)
- 2. Wild-type cell line

### **Parental Cell Line**

Human cell line supplied by the client

### **Validation Methods**

RT-qPCR, Western blotting (WB)

# **Shipping**

Shipped on Dry Ice.


### **Instructions For Use**

This knockdown cell line should be paired with wild-type cell line for use.


**Note:** This product is for research use only.

#### Validation Data

# **Human IGFBP7 Knockdown Cell Line (WB-Validated)**



RT-qPCR analysis. HT-1080 cells were infected with IGFBP7-specific shRNA lentiviral particles, total RNA was extracted from wild-type and knockdown cells, RT-qPCR was performed using gene-specific primers.  $\Delta$ Ct (CtKD-CtWT) was used to calculate mRNA reduction (%) between wild-type and knockdown cells using the following formula:  $(1-1/2\Delta$ Ct) x 100%.



Western blotting analysis. IGFBP7 protein expression in wild-type (WT) and shRNA knockdown (KD) HT-1080 cells was detected using Western blotting.  $\beta$ -Tubulin served as a loading control. The blots were incubated with primary antibodies against IGFBP7 and  $\beta$ -Tubulin, respectively, followed by incubating with HRP-conjugated goat anti-rabbit secondary antibody. Images were developed using FeQ<sup>TM</sup> ECL Substrate Kit.